We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SELLAS Life Sciences Group Inc | NASDAQ:SLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 4.84% | 1.30 | 1.28 | 1.29 | 1.4399 | 1.12 | 1.30 | 9,517,165 | 00:59:30 |
As filed with the Securities and Exchange Commission on July 11, 2018
Registration Statement No. 333-225140
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1
to
FORM S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
SELLAS Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 20-8099512 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
315 Madison Avenue, 4th Floor
New York, NY 10017
(917) 438-4353
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Angelos M. Stergiou, M.D., Sc.D., h.c.
President and Chief Executive Officer
SELLAS Life Sciences Group, Inc.
315 Madison Avenue, 4th Floor
New York, NY 10017
(917) 438-4353
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Yvan-Claude Pierre, Esq. Marianne Sarrazin, Esq. Cooley LLP 1114 Avenue of the Americas New York, NY 10036 Tel: (212) 479-6000 |
Barbara Wood, Esq. Executive Vice President, General Counsel & Secretary SELLAS Life Sciences Group, Inc. 315 Madison Avenue, 4th Floor New York, NY 10017 Tel: (917) 438-4353 |
Glenn R. Pollner, Esq. Gibson, Dunn & Crutcher LLP 200 Park Avenue New York, NY 10166 Tel: (212) 351-4000 |
Approximate date of commencement of proposed sale to public: As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-225140)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ (Do not check if a smaller reporting company) | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registration Statement shall become effective upon filing in accordance with Rule 462(d) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to Form S-1 Registration Statement (File No. 333-225140) is filed pursuant to Rule 462(d) solely to add an updated Exhibit 5.1 with respect to such Registration Statement.
Part II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. | Exhibits and Financial Statement Schedules. |
II-1
II-2
II-3
II-4
II-5
II-6
II-7
^ | The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |
+ | Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. |
II-8
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the city of New York, New York, on this 11 th day of July, 2018.
SELLAS LIFE SCIENCES GROUP, INC. | ||
By: | /s/ Angelos M. Stergiou | |
Name: |
Angelos M. Stergiou, M.D., Sc.D., h.c. | |
Title: |
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, as amended, this post-effective amendment No. 1 to registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
/s/ Angelos M. Stergiou Angelos M. Stergiou, M.D., Sc.D., h.c. |
President, Chief Executive Officer and Director
|
July 11, 2018 | ||
/s/ Gene Mack Gene Mack |
Chief Financial Officer and Treasurer
|
July 11, 2018 | ||
/s/ * Jane Wasman |
Chairman of the Board |
July 11, 2018 | ||
/s/ * Stephen F. Ghiglieri |
Director |
July 11, 2018 | ||
/s/ * Fabio López |
Director |
July 11, 2018 | ||
/s/ * David A. Scheinberg, M.D., Ph.D. |
Director |
July 11, 2018 | ||
/s/ * Robert L. Van Nostrand |
Director |
July 11, 2018 | ||
/s/ * John Varian |
Director |
July 11, 2018 |
*By: | /s/ Angelos M. Stergiou | |
Angelos M. Stergiou, M.D., Sc.D., h.c. | ||
Attorney-in-Fact |
1 Year SELLAS Life Sciences Chart |
1 Month SELLAS Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions